Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2018
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2018
SUMMARY
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 28 molecules. The latest report Tyrosine Protein Kinase JAK1 - Pipeline Review, H1 2018, outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body.
The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 5, 4, 9 and 2 respectively. Report covers products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Hematological Disorders, Ophthalmology and Respiratory which include indications Rheumatoid Arthritis, Atopic Dermatitis, Alopecia, Ulcerative Colitis, Crohn’s Disease (Regional Enteritis), Diffuse Large B-Cell Lymphoma, Psoriasis, Psoriatic Arthritis, Vitiligo, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Ankylosing Spondylitis (Bekhterev's Disease), B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Giant Cell Arteritis, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Mantle Cell Lymphoma, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Peripheral T-Cell Lymphomas (PTCL), Relapsed Multiple Myeloma, Waldenstrom Macroglobulinemia, Androgenic Alopecia, Arthritis, Auto Inflammatory Disease, B-Cell Chronic Lymphocytic Leukemia, Breast Cancer, Cancer Anorexia-Cachexia Syndrome, Chronic Asthma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Dermatomyositis, Eczema, Endometrial Cancer, Essential Thrombocythemia, Follicular Lymphoma, Gastric Cancer, Hairy Cell Leukemia, Hypopharyngeal Cancer, Inflammation, Inflammatory Bowel Disease, Laryngeal Cancer, Lupus Erythematosus, Lupus Nephritis, Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Prostate Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Myelofibrosis, Non-Hodgkin Lymphoma, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Plaque Psoriasis (Psoriasis Vulgaris), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Sicca Syndrome (Sjogren), Spondyloarthritis (Spondyloarthropathy), Systemic Lupus Erythematosus, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Thalassemia, Thrombocythemia Myelofibrosis, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Uveitis.
Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 28 molecules. The latest report Tyrosine Protein Kinase JAK1 - Pipeline Review, H1 2018, outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body.
The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 5, 4, 9 and 2 respectively. Report covers products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Hematological Disorders, Ophthalmology and Respiratory which include indications Rheumatoid Arthritis, Atopic Dermatitis, Alopecia, Ulcerative Colitis, Crohn’s Disease (Regional Enteritis), Diffuse Large B-Cell Lymphoma, Psoriasis, Psoriatic Arthritis, Vitiligo, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Ankylosing Spondylitis (Bekhterev's Disease), B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Giant Cell Arteritis, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Mantle Cell Lymphoma, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Peripheral T-Cell Lymphomas (PTCL), Relapsed Multiple Myeloma, Waldenstrom Macroglobulinemia, Androgenic Alopecia, Arthritis, Auto Inflammatory Disease, B-Cell Chronic Lymphocytic Leukemia, Breast Cancer, Cancer Anorexia-Cachexia Syndrome, Chronic Asthma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Dermatomyositis, Eczema, Endometrial Cancer, Essential Thrombocythemia, Follicular Lymphoma, Gastric Cancer, Hairy Cell Leukemia, Hypopharyngeal Cancer, Inflammation, Inflammatory Bowel Disease, Laryngeal Cancer, Lupus Erythematosus, Lupus Nephritis, Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Prostate Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Myelofibrosis, Non-Hodgkin Lymphoma, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Plaque Psoriasis (Psoriasis Vulgaris), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Sicca Syndrome (Sjogren), Spondyloarthritis (Spondyloarthropathy), Systemic Lupus Erythematosus, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Thalassemia, Thrombocythemia Myelofibrosis, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Uveitis.
Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AbbVie Inc
Aclaris Therapeutics Inc
Astellas Pharma Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
CJ HealthCare Corp
Concert Pharmaceuticals Inc
Eli Lilly and Co
Galapagos NV
Han Wha Pharma Co Ltd
Incyte Corp
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
LEO Pharma A/S
Nissan Chemical Industries Ltd
Pfizer Inc
Portola Pharmaceuticals Inc
Sareum Holdings Plc
Theravance Biopharma Inc
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Drug Profiles
ABBV-599 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-0449 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-1480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-4205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
baricitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cerdulatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-15314 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTP-543 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
delgocitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-52793 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
itacitinib adipate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LP-0184 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NIP-565 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
peficitinib hydrobromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-04965842 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06700841 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-20347 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SART-29 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-0302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK1 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK1 and JAK3 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Jak1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-1473 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
upadacitinib tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Apr 25, 2018: Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 25, 2018: AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients
Apr 25, 2018: AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients
Apr 25, 2018: Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia Areata
Apr 23, 2018: FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
Apr 23, 2018: Aclaris Therapeutics Announces First Patient Dosed in a Pilot Study with ATI-502 Topical in Patients with Androgenetic Alopecia
Apr 09, 2018: Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis
Feb 17, 2018: AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting
Feb 16, 2018: AbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn’s Disease at 52 Weeks
Feb 14, 2018: Lilly to Showcase New Data for baricitinib at AAD Annual Meeting
Feb 14, 2018: Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
Feb 12, 2018: AbbVie to Present Data on Upadacitinib at 2018 American Academy of Dermatology Annual Meeting
Feb 12, 2018: Concert Pharmaceuticals Announces Initiation of Enrollment in Second Cohort of CTP-543 Phase 2a Trial for Alopecia Areata
Feb 08, 2018: Astellas Announce Top-Line Results for Two Phase 3 Trials of Peficitinib in Rheumatoid Arthritis Patients with Inadequate Response to Existing Therapy
Jan 12, 2018: Top-line Results of the Topical JTE-052 JAK Inhibitor Phase 3 Clinical Study (Comparative Study) in Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AbbVie Inc
Aclaris Therapeutics Inc
Astellas Pharma Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
CJ HealthCare Corp
Concert Pharmaceuticals Inc
Eli Lilly and Co
Galapagos NV
Han Wha Pharma Co Ltd
Incyte Corp
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
LEO Pharma A/S
Nissan Chemical Industries Ltd
Pfizer Inc
Portola Pharmaceuticals Inc
Sareum Holdings Plc
Theravance Biopharma Inc
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Drug Profiles
ABBV-599 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-0449 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-1480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-4205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
baricitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cerdulatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-15314 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTP-543 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
delgocitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-52793 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
itacitinib adipate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LP-0184 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NIP-565 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
peficitinib hydrobromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-04965842 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06700841 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-20347 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SART-29 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-0302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK1 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK1 and JAK3 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Jak1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-1473 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
upadacitinib tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Apr 25, 2018: Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 25, 2018: AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients
Apr 25, 2018: AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients
Apr 25, 2018: Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia Areata
Apr 23, 2018: FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
Apr 23, 2018: Aclaris Therapeutics Announces First Patient Dosed in a Pilot Study with ATI-502 Topical in Patients with Androgenetic Alopecia
Apr 09, 2018: Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis
Feb 17, 2018: AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting
Feb 16, 2018: AbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn’s Disease at 52 Weeks
Feb 14, 2018: Lilly to Showcase New Data for baricitinib at AAD Annual Meeting
Feb 14, 2018: Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
Feb 12, 2018: AbbVie to Present Data on Upadacitinib at 2018 American Academy of Dermatology Annual Meeting
Feb 12, 2018: Concert Pharmaceuticals Announces Initiation of Enrollment in Second Cohort of CTP-543 Phase 2a Trial for Alopecia Areata
Feb 08, 2018: Astellas Announce Top-Line Results for Two Phase 3 Trials of Peficitinib in Rheumatoid Arthritis Patients with Inadequate Response to Existing Therapy
Jan 12, 2018: Top-line Results of the Topical JTE-052 JAK Inhibitor Phase 3 Clinical Study (Comparative Study) in Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.2), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.3), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Products under Development by Companies, H1 2018 (Contd.4), H1 2018
Products under Development by Companies, H1 2018 (Contd.5), H1 2018
Products under Development by Companies, H1 2018 (Contd.6), H1 2018
Products under Development by Companies, H1 2018 (Contd.7), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AbbVie Inc, H1 2018
Pipeline by Aclaris Therapeutics Inc, H1 2018
Pipeline by Astellas Pharma Inc, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Bristol-Myers Squibb Co, H1 2018
Pipeline by CJ HealthCare Corp, H1 2018
Pipeline by Concert Pharmaceuticals Inc, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by Galapagos NV, H1 2018
Pipeline by Han Wha Pharma Co Ltd, H1 2018
Pipeline by Incyte Corp, H1 2018
Pipeline by Japan Tobacco Inc, H1 2018
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Pipeline by LEO Pharma A/S, H1 2018
Pipeline by Nissan Chemical Industries Ltd, H1 2018
Pipeline by Pfizer Inc, H1 2018
Pipeline by Portola Pharmaceuticals Inc, H1 2018
Pipeline by Sareum Holdings Plc, H1 2018
Pipeline by Theravance Biopharma Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018
Discontinued Products, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.2), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.3), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Products under Development by Companies, H1 2018 (Contd.4), H1 2018
Products under Development by Companies, H1 2018 (Contd.5), H1 2018
Products under Development by Companies, H1 2018 (Contd.6), H1 2018
Products under Development by Companies, H1 2018 (Contd.7), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AbbVie Inc, H1 2018
Pipeline by Aclaris Therapeutics Inc, H1 2018
Pipeline by Astellas Pharma Inc, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Bristol-Myers Squibb Co, H1 2018
Pipeline by CJ HealthCare Corp, H1 2018
Pipeline by Concert Pharmaceuticals Inc, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by Galapagos NV, H1 2018
Pipeline by Han Wha Pharma Co Ltd, H1 2018
Pipeline by Incyte Corp, H1 2018
Pipeline by Japan Tobacco Inc, H1 2018
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Pipeline by LEO Pharma A/S, H1 2018
Pipeline by Nissan Chemical Industries Ltd, H1 2018
Pipeline by Pfizer Inc, H1 2018
Pipeline by Portola Pharmaceuticals Inc, H1 2018
Pipeline by Sareum Holdings Plc, H1 2018
Pipeline by Theravance Biopharma Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018
Discontinued Products, H1 2018 (Contd.1), H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
COMPANIES MENTIONED
AbbVie Inc
Aclaris Therapeutics Inc
Astellas Pharma Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
CJ HealthCare Corp
Concert Pharmaceuticals Inc
Eli Lilly and Co
Galapagos NV
Han Wha Pharma Co Ltd
Incyte Corp
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
LEO Pharma A/S
Nissan Chemical Industries Ltd
Pfizer Inc
Portola Pharmaceuticals Inc
Sareum Holdings Plc
Theravance Biopharma Inc
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
COMPANIES MENTIONED
AbbVie Inc
Aclaris Therapeutics Inc
Astellas Pharma Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
CJ HealthCare Corp
Concert Pharmaceuticals Inc
Eli Lilly and Co
Galapagos NV
Han Wha Pharma Co Ltd
Incyte Corp
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
LEO Pharma A/S
Nissan Chemical Industries Ltd
Pfizer Inc
Portola Pharmaceuticals Inc
Sareum Holdings Plc
Theravance Biopharma Inc
